NASDAQ · CDLX

Cardlytics, Inc.

$3.74 +$0.12 (+3.31%) 1D Market open

Key Metrics

$21.02M
Market cap
P/E · TTM
$205.69M
Revenue · TTM
−$94.69M
Net income
EPS · TTM $-1.83
Dividend yield
Free cash flow $9.97M
Beta · 1Y 2.49
EBITDA · TTM −$80.63M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Apr 6 high, the share price fell 69%.

    Peak close $11.80 on Apr 6; trough close $3.62 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -69%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 20
    The stock moved +21.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 20
  • May 8
    The stock moved -18.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 8

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$21.02M
Enterprise value$165.42M
Shares outstanding5.8M
52-wk range$0.85 – $15.55
Avg volume · 20D982.8K
Net cash −$144.40M
Book value / share$-0.08
IndustryServices-Computer Programming, Data Processing, Etc.
ExchangeNASDAQ
About Cardlytics, Inc.
IPO dateFeb 9, 2018
Employees224

Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.10
P/FCF2.11
EV/EBITDA
EV/Sales0.80
Graham №

Profitability

Gross
Operating -50.6%
Net -46.0%
FCF 4.8%
ROE / ROIC -287.0% · —

Financial Health

Current ratio2.17
Quick ratio
Debt / equity-51.01
Debt / EBITDA -2.53
Net cash −$144.40M
Working capital$69.17M

Cash Flow · TTM

Operating CF $10.35M
Capex −$389.00K
Free cash flow $9.97M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

-7.6
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings